James E Flynn Insider Trading $CAQ VIA Pharmaceuticals, Inc.
Get free email notifications about insider trading for James E Flynn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James E Flynn. James E Flynn is 10% Owner in CAS MEDICAL SYSTEMS INC ($CAMY.OB) and 10% Owner in AxoGen, Inc. ($LECT) and 10% Owner in PAR PHARMACEUTICAL COMPANIES, INC. ($PRX) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in STREAMLINE HEALTH SOLUTIONS INC. ($LANV) and 10% Owner in ANTARES PHARMA, INC. ($ATRS) and 10% Owner in VIA Pharmaceuticals, Inc. ($CAQ) and 10% Owner in DUSA PHARMACEUTICALS INC ($DUSA) and 10% Owner in HI TECH PHARMACAL CO INC ($HITK) and 10% Owner in AVADEL PHARMACEUTICALS PLC ($AVDL) and 10% Owner in INSPIRE PHARMACEUTICALS INC ($ISPH) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARENA PHARMACEUTICALS INC ($ARNA) and 10% Owner in ISTA PHARMACEUTICALS INC ($ISTA) and 10% Owner in MEDICINES CO /DE ($MDCO) and 10% Owner in THIRD WAVE TECHNOLOGIES INC /WI ($TWTI) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Director in Talon Therapeutics, Inc. ($EMLR) and 10% Owner in LUMOS PHARMA, INC. ($NLNK) and 10% Owner in NITROMED INC ($NTMD) and 10% Owner in XENOPORT INC ($XNPT) and 10% Owner in EMAGEON INC ($EMAG) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ALIMERA SCIENCES INC ($ALIM) and 10% Owner in NeuroMetrix, Inc. ($NURO) and 10% Owner in NxStage Medical, Inc. ($NXTM) and 10% Owner in aTYR PHARMA INC ($LIFE) and 10% Owner in Vanda Pharmaceuticals Inc. ($VNDA) and 10% Owner in XERIS PHARMACEUTICALS INC ($XERS) and Director in PROTEON THERAPEUTICS INC ($PRTO) and 10% Owner in eHealth, Inc. ($EHTH) and 10% Owner in ZAFGEN, INC. ($ZFGN) and 10% Owner in NeurogesX Inc ($NGSX) and 10% Owner in Invuity, Inc. ($IVTY) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and 10% Owner in TriVascular Technologies, Inc. ($TRIV) and 10% Owner in Auspex Pharmaceuticals, Inc. ($ASPX) and 10% Owner in Neos Therapeutics, Inc. ($NEOS) and 10% Owner in Schrodinger, Inc. ($SDGR) and 10% Owner in CytomX Therapeutics, Inc. ($CTMX) and Director in Acutus Medical, Inc. ($AFIB) and 10% Owner in Annexon, Inc. ($ANNX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and 10% Owner in Syros Pharmaceuticals, Inc. ($SYRS) and 10% Owner in Mallinckrodt plc ($MNK) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Adverum Biotechnologies, Inc. ($AAVL) and 10% Owner in REGENXBIO Inc. ($RGNX) and 10% Owner in Recro Pharma, Inc. ($REPH) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and Director in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in ShockWave Medical, Inc. ($SWAV) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and 10% Owner in Editas Medicine, Inc. ($EDIT) and Director in AveXis, Inc. ($AVXS) and 10% Owner in ARVINAS INC. ($ARVN) and 10% Owner in Homology Medicines, Inc. ($FIXX) and Director in Homology Medicines, Inc. ($FIXX) and Director in Oncorus, Inc. ($ONCR) and 10% Owner in Revolution Medicines, Inc. ($RVMD) and 10% Owner in Black Diamond Therapeutics, Inc. ($BDTX) and 10% Owner in Frequency Therapeutics, Inc. ($FREQ) and Director in DFB Healthcare Acquisitions Corp. ($DFBH) and 10% Owner in Generation Bio Co. ($GBIO) and 10% Owner in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and 10% Owner in Cabaletta Bio, Inc. ($CABA) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and 10% Owner in Edgewise Therapeutics, Inc. ($EWTX) and Director in DFP HEALTHCARE ACQUISITIONS CORP. ($DFPH) and Director in Deerfield Healthcare Technology Acquisitions Corp. ($DFHT) and 10% Owner in Terns Pharmaceuticals, Inc. ($TERN).
James E Flynn in VIA Pharmaceuticals, Inc.
Trading Symbol: CAQIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of James E Flynn: 10% Owner
Holdings: 1,244,708 shares
Latest Transaction: Nov 07 2007
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of James E Flynn in VIA Pharmaceuticals, Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACRS, AFIB, DFBH, ADVM, ALIM, ALPN, ANNX, ATRS, ARNA, ARVN, LIFE, BOLD, ASPX, AVDL, AVXS, LECT, BDTX, CABA, CAMY.OB, CBIO, CNST, CYCC, CTMX, DFHTW, DFPHU, DRNA, DUSA, DVAX, EWTX, EDIT, EHTH, EMAG, FCSC, FREQ, GBIO, HITK, FIXX, ISPH, IVTY, ISTA, KNSA, LRMR, LOXO, NLNK, MNK, MDCO, MIRM, NEOS, NGSX, NURO, NTMD, NKTX, NXTM, ONCR, PRX, TARA, REPH, RGNX, RVMD, RYTM, RIGL, SDGR, SWAV, STDY, LANV, SYRS, EMLR, TERN, TWTI, TRIV, VNDA, CAQ, HOWL, XNPT, XERS
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Nov 07 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.21 | 39,904 | 128,092 | 1,244,708 | 1.3 M to 1.2 M (-3.11 %) |
Nov 07 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.38 | 64 | 216 | 1,284,612 | 1.3 M to 1.3 M (0.00 %) |
Nov 07 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.21 | 23,234 | 74,581 | 724,779 | 748 K to 724.8 K (-3.11 %) |
Nov 07 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.38 | 36 | 122 | 748,013 | 748 K to 748 K (0.00 %) |
Nov 02 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.97 | 74 | 293 | 1,284,676 | 1.3 M to 1.3 M (-0.01 %) |
Nov 02 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.97 | 42 | 167 | 748,049 | 748.1 K to 748 K (-0.01 %) |
Oct 30 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.92 | 1,459 | 5,725 | 1,284,750 | 1.3 M to 1.3 M (-0.11 %) |
Oct 30 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.92 | 848 | 3,327 | 748,091 | 748.9 K to 748.1 K (-0.11 %) |
Oct 26 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.88 | 1,359 | 5,267 | 1,286,209 | 1.3 M to 1.3 M (-0.11 %) |
Oct 26 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.91 | 8,322 | 32,576 | 1,287,568 | 1.3 M to 1.3 M (-0.64 %) |
Oct 26 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.97 | 64 | 254 | 1,295,890 | 1.3 M to 1.3 M (0.00 %) |
Oct 26 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.98 | 445 | 1,771 | 1,295,954 | 1.3 M to 1.3 M (-0.03 %) |
Oct 26 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.88 | 790 | 3,062 | 748,939 | 749.7 K to 748.9 K (-0.11 %) |
Oct 26 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.91 | 4,845 | 18,966 | 749,729 | 754.6 K to 749.7 K (-0.64 %) |
Oct 26 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.97 | 36 | 143 | 754,574 | 754.6 K to 754.6 K (0.00 %) |
Oct 26 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.98 | 259 | 1,031 | 754,610 | 754.9 K to 754.6 K (-0.03 %) |
Oct 19 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.98 | 582 | 2,316 | 1,296,399 | 1.3 M to 1.3 M (-0.04 %) |
Oct 19 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 4.03 | 3,430 | 13,807 | 1,296,981 | 1.3 M to 1.3 M (-0.26 %) |
Oct 19 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 3.98 | 338 | 1,345 | 754,869 | 755.2 K to 754.9 K (-0.04 %) |
Oct 19 2007 | CAQ | VIA Pharmaceutical ... | Flynn James E | 10% Owner | Sell | S | 4.03 | 1,995 | 8,030 | 755,207 | 757.2 K to 755.2 K (-0.26 %) |
Page: 1